新辅助化疗后切除IDH突变胶质瘤患者系列的肿瘤学、认知与就业结局
这项回顾性研究纳入2011年6月至2021年12月间6例IDH突变胶质瘤患者,先接受新辅助化疗(5例替莫唑胺、1例PCV)后行清醒手术。中位肿瘤体积缩小47%,1例完全切除、4例次全切除、1例部分切除;化疗期间未见严重不良事件,4个月时2例神经心理评估灵活性恶化,术前全职工作的4例中3例在7至10个月后恢复全职工作。作者认为对直接手术不合适的IDH突变胶质瘤患者可提供新辅助化疗后最大安全切除,但样本量有限需更多研究。
要点
- 6例IDH突变胶质瘤经新辅助化疗后中位肿瘤体积缩小47%,1例完全切除、4例次全切除、1例部分切除。
- 化疗期间未见严重不良事件;术后4个月神经心理评估2例灵活性恶化(一例词语流畅性、一例连线测验)。
- 术前全职工作的4例中3例在7至10个月后恢复全职工作。
核心结论
- 对直接手术不合适的IDH突变胶质瘤患者,可提供新辅助化疗后最大安全切除。
- 鉴于样本量有限,需更多研究。
研究设计与样本
- 回顾性研究,时间范围为2011年6月至2021年12月。
- 纳入6例接受新辅助化疗后行清醒手术切除的IDH突变胶质瘤患者,其中3例少突胶质细胞瘤、3例星形细胞瘤。
- 新辅助化疗方案为替莫唑胺5例、PCV 1例。
- MRI影像随访每3至6个月进行。
- 所有患者术前、术后及后续随访接受神经心理评估,并定期访谈临床与就业状态。
主要发现
- 中位肿瘤体积缩小47%,实现完全切除1例、次全切除4例、部分切除1例。
- 化疗期间未见严重不良事件。
- 术后4个月神经心理评估显示2例灵活性恶化,其中1例为词语流畅性、1例为连线测验。
- 术前全职工作的4例患者中,3例在7至10个月延迟后恢复全职工作。
局限性
- 作者指出鉴于样本量有限,需更多研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Maximal safe tumor resection is the first line of treatment for IDH-mutated gliomas. However, when upfront surgical resection is deemed unsatisfactory due to tumor size and location, chemotherapy could represent an interesting alternative for reducing glioma extension and allowing for a safer and more efficient removal. METHODS: We performed a retrospective study (June 2011 to December 2021) on patients with IDH-mutated gliomas undergoing chemotherapy with a neoadjuvant intent, followed by surgical excision in awake conditions. MRI-imaging follow-up was conducted every 3-6 months. Neuropsychological assessments (NPSA) were performed for all patients before surgery, during post-operative period, and at later follow-up, and patients were periodically interviewed about their clinical and job status. RESULTS: We included 6 patients who underwent awake surgery after neoadjuvant chemotherapy (temozolomide in 5 cases, PCV in 1 case) for an IDH-mutated glioma (3 oligodendrogliomas and 3 astrocytomas). Median tumor volume reduction was 47%, allowing for complete resection in one patient, subtotal resection in 4 patients, and partial resection in 1 patient. No major adverse effects were observed under chemotherapy. At the 4 months NPSA, a worsening of flexibility was observed in 2 patients (verbal fluencies in one case and trail making test in the other). Three out of the four patients working full time before procedure resumed their job full time, after a 7 to 10 months delay. CONCLUSION: Neoadjuvant chemotherapy followed by maximal safe resection can be offered to patients affected by IDH-mutated gliomas for whom upfront surgery would be inadequate. More studies are necessary given the limited size of our sample.
引用
- Bursi M, Rizzo C, Barberis M, et al. Oncological, cognitive, and employment outcomes in a series of patients with IDH-mutated glioma resected following neoadjuvant chemotherapy. Acta Neurochir (Wien). 2023. PMID: 37482554. doi:10.1007/s00701-023-05711-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。